HELPNYSECybin Inc. Common Stock

HELP price activity

Last Price

Change (24hr)

USD (%)

Volume

Volume (4w avg)

Previous Close

N/A

Last Trade

HELP price performance

37.72%

84.08%

35.7%

YTD

46.25%

HELP price fundamentals

N/A

Shares Issued

N/A

Earnings Per Share (EPS)

N/A

Dividends Per Share (DPS)

N/A

P/E Ratio

Price market cap

Market cap

N/A

US-NYSE rank

N/A

Sector Rank

N/A

HELP details

View company website

View US-NYSE Official Page

HELP Market Signals

More ways to discover

Browse United States news Discover NYSE signals Browse all NYSE stocks

Cybin Inc. Common Stock (US-NYSE: HELP)

Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.

Price: $11.10

Sector: Healthcare — Biotechnology